Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
about
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentMDV3100 for the treatment of prostate cancer.COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.Androgen receptor antagonists in castration-resistant prostate cancer.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.Saudi Oncology Society clinical management guidelines for prostate cancer.Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.Current management of prostate cancer: dilemmas and trialsCellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.Emerging biological observations in prostate cancer.Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.Current treatment strategies for castration-resistant prostate cancerThe changing therapeutic landscape of castration-resistant prostate cancer.A new era for castrate resistant prostate cancer: a treatment review and update.Castration-resistant metastatic prostate cancer: current status and treatment possibilities.Management of advanced prostate cancer in senior adults: the new landscape.The role of enzalutamide in the treatment of castration-resistant prostate cancer.Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.Radium-223 for the treatment of prostate cancer.Overview of the latest treatments for castration-resistant prostate cancer.The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?Recent advances revolutionize treatment of metastatic prostate cancer.Novel agents in the management of castration resistant prostate cancer.Evolution of androgen receptor targeted therapy for advanced prostate cancer.Advances in systemic therapies for metastatic castration-resistant prostate cancer.Nonmetastatic castration-resistant prostate cancer.Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistanceUroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate CancerIs there an anti-androgen withdrawal syndrome for enzalutamide?Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
P2860
Q26739708-B7A96C83-EF71-4ADB-9F4C-D3EC3E0AB5F0Q26747782-9F0C977B-FC9C-415A-B7E4-C14DB0C0B659Q27009424-86EA3224-0B4B-4045-B0BF-5FBA03A87AC7Q34245740-6C98A780-458E-4A0A-AD8D-F988AAB970A5Q34309132-6FD186AB-180C-4C5E-AA81-B607722BAECAQ34323656-78D1F274-9D39-4A72-AEE5-F70FB8E019CFQ34437308-4BFF4FB2-D97E-4E0F-83FD-0787ED0AE817Q34464312-31AE1561-DF4A-404D-BAE1-142A2DD90D01Q34997355-4DEB2261-8AF9-442F-AC26-3085704349DFQ35582133-3C15296E-C2D7-4112-B22D-DEEA2F161345Q35737858-0A37B5F9-A69D-4BDB-AE79-6996BEDA8661Q36284625-7CF92C30-C735-4349-BF49-E3AEE8FA333EQ36285594-CA4BA18E-E7D2-466E-B6D9-104F97529C5EQ37102535-DBE2A53A-9888-4DE4-93AD-7AD577C6897FQ37457995-A897CE42-04F1-4AE6-B7B7-964869E5DEC5Q37656229-C23DF8ED-4E58-44C1-A44C-A1F97A1A7056Q37800061-DBB558E2-08E4-4952-BB5C-B63866794C9BQ37860950-728ABE76-606A-48E9-BDC9-106BD6AE5C2EQ37913983-C67FCEC4-A0C0-482E-B9EA-E677AA25B68AQ37985547-45467574-E483-4E2B-9476-74AF7D4AA42AQ37989075-C1E20AFF-80A1-4FF2-8D64-98453E30E80DQ38046826-6CBEF000-C3B8-4A35-810A-5B2C477673E1Q38048881-2A9477BB-5363-47BE-8842-BB86A508D24AQ38069186-9278BB05-DB8A-4D4B-9C98-B770F6BF5C5AQ38073823-F7D7A2C8-57DF-4D74-A855-93BB82F87222Q38116754-8FFA8DB7-D1DE-4DAD-9A74-969630A9DF43Q38116790-58B3B32F-C168-43EC-AEE0-2EED93DC342FQ38125501-A91AB707-85C0-4BFB-8F41-24D9A0096F41Q38209656-66F6E744-580B-4CAC-903A-234CFABBFCCCQ38212716-F4ADDF62-1242-4F14-AF53-DB3725E2BC65Q38282461-8966FA4B-D541-45F6-AD6B-5935587A4A28Q38306052-8A3310D1-9E33-4A72-B409-04D3861B193CQ38309205-234269A0-14E6-4382-B2B3-1E46AF77FA4EQ38410885-CC264B9A-D1DF-47B5-B40F-B5655D6A5A1DQ38537545-218C2D88-1097-4E19-BF22-32E82F96F0BFQ38680652-D6C78E18-EB26-40E7-BF97-F1CE822B7291Q38779039-43259337-5BC9-4103-AD8D-D52105FDA900Q38833292-65FA36F6-8B1D-4850-BAAD-7F117843D6A9Q39217798-BAA25AA0-22C7-4CFE-B5B5-EA04644C1F2FQ39347702-FD246866-1AB4-4746-85F8-36148A0CAB86
P2860
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@ast
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@en
type
label
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@ast
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@en
prefLabel
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@ast
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@en
P2093
P2860
P356
P1433
P1476
Antiandrogen withdrawal in cas ...... cology Group trial (SWOG 9426)
@en
P2093
A Oliver Sartor
Catherine M Tangen
Derek Raghavan
E David Crawford
Glenn M Mills
Joseph A Fontana
Maha H A Hussain
Mario A Eisenberger
Minoti Parab
Robert A Chapman
P2860
P304
P356
10.1002/CNCR.23473
P407
P50
P577
2008-06-01T00:00:00Z